» Articles » PMID: 34600526

Cell-free DNA and Circulating Tumor Cell Kinetics in a Pre-clinical Head and Neck Cancer Model Undergoing Radiation Therapy

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2021 Oct 3
PMID 34600526
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Monitoring circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), known as liquid biopsies, continue to be developed as diagnostic and prognostic markers for a wide variety of cancer indications, mainly due to their minimally invasive nature and ability to offer a wide range of phenotypic and genetic information. While liquid biopsies maintain significant promising benefits, there is still limited information regarding the kinetics of ctDNA and CTCs following radiation therapy which remains a vital treatment modality in head and neck cancers. This study aims to describe the kinetics of ctDNA and CTCs following radiation exposure in a preclinical rabbit model with VX2 induced buccal carcinoma.

Methods: Seven rabbits were inoculated with VX2 cells in the buccal mucosa and subjected to radiation. At selected time points, blood sampling was performed to monitor differing levels of ctDNA and CTC. Plasma ctDNA was measured with quantitative PCR for papillomavirus E6 while CTCs were quantified using an immunomagnetic nanoparticles within a microfluidic device. Comparisons of CTC detection with EpCAM compared to multiple surface markers (EGFR, HER2 and PSMA) was evaluated and correlated with the tumor size.

Results: Plasma ctDNA reflects the overall tumor burden within the animal model. Analysis of correlations between ctDNA with tumor and lymph node volumes showed a positive correlation (R = 0.452 and R = 0.433 [p < 0.05]), respectively. Over the course of treatment, ctDNA levels declined and quickly becomes undetectable following tumor eradication. While during the course of treatment, ctDNA levels were noted to rise particularly upon initiation of radiation following scheduled treatment breaks. Levels of CTCs were observed to increase 1 week following inoculation of tumor to the primary site. For CTC detection, the use of multiple surface markers showed a greater sensitivity when compared to detection using only EpCAM. Plasma CTC levels remained elevated following radiation therapy which may account for an increased shedding of CTCs following radiation.

Conclusion: This study demonstrates the utility of ctDNA and CTCs detection in response to radiation treatment in a preclinical head and neck model, allowing for better understanding of liquid biopsy applications in both clinical practice and research development.

Citing Articles

Early Circulating Tumor DNA Kinetics as a Dynamic Biomarker of Cancer Treatment Response.

Li A, Lou E, Leder K, Foo J JCO Clin Cancer Inform. 2025; 9:e2400160.

PMID: 40053881 PMC: 11895822. DOI: 10.1200/CCI-24-00160.


COVID-19 Pandemic Conditions Affecting QoL and Mental Health of Oncology Patients in Poland.

Dzialach E, Malchrowicz-Mosko E, Rozmiarek M, Meller J, Juraszek P, Nowara E Cancers (Basel). 2025; 17(4).

PMID: 40002257 PMC: 11852427. DOI: 10.3390/cancers17040662.


Early ctDNA kinetics as a dynamic biomarker of cancer treatment response.

Li A, Lou E, Leder K, Foo J bioRxiv. 2024; .

PMID: 39005329 PMC: 11244961. DOI: 10.1101/2024.07.01.601508.


Radiation Biological Toximetry Using Circulating Cell-Free DNA (cfDNA) for Rapid Radiation/Nuclear Triage.

Okunieff P, Swarts S, Fenton B, Zhang S, Zhang Z, Rice L Radiat Res. 2024; 202(1):70-79.

PMID: 38661544 PMC: 11346512. DOI: 10.1667/RADE-23-00159.1.


Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma.

de Bruyn D, van Poppelen N, Brands T, van den Boom S, Eikenboom E, Wagner A Invest Ophthalmol Vis Sci. 2024; 65(2):11.

PMID: 38319670 PMC: 10854420. DOI: 10.1167/iovs.65.2.11.


References
1.
Kulasinghe A, Warkiani M, Punyadeera C . The Isolation and Characterization of Circulating Tumor Cells from Head and Neck Cancer Patient Blood Samples Using Spiral Microfluidic Technology. Methods Mol Biol. 2019; 2054:129-136. DOI: 10.1007/978-1-4939-9769-5_8. View

2.
Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L . Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 2015; 9(9):1773-82. PMC: 5528721. DOI: 10.1016/j.molonc.2015.05.009. View

3.
Allard W, Matera J, Miller M, Repollet M, Connelly M, Rao C . Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904. DOI: 10.1158/1078-0432.CCR-04-0378. View

4.
Mittal V . Epithelial Mesenchymal Transition in Tumor Metastasis. Annu Rev Pathol. 2018; 13:395-412. DOI: 10.1146/annurev-pathol-020117-043854. View

5.
Montero P, Patel S . Cancer of the oral cavity. Surg Oncol Clin N Am. 2015; 24(3):491-508. PMC: 5018209. DOI: 10.1016/j.soc.2015.03.006. View